SCHEMBL244718

SCHEMBL244718

N[C@H](Cc1ccc(Br)cc1)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.69
PTGS1 P23219 3/20 0.68
ALPI P09923 1/20 0.68
PKM P14618 1/20 0.68
XIAP P98170 1/20 0.68
PTPRC P08575 1/20 0.58
HIF1A Q16665 4/20 0.58
ALOX15 P16050 3/20 0.58
KDM4E B2RXH2 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
HSD17B10 Q99714 2/20 0.58
USP2 O75604 1/20 0.58
EGFR P00533 1/20 0.58
LCK P06239 1/20 0.58
FYN P06241 1/20 0.58
ADORA3 P0DMS8 1/20 0.58
HTR2A P28223 1/20 0.58
PTGS2 P35354 1/20 0.58
RECQL P46063 1/20 0.58
TPH1 P17752 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL44832 1.00 SLC7A5 (0.69) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL44831 1.00 SLC7A5 (0.69) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL975336 0.98 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL27515070 0.98 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL5878327 0.98 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31370558 0.94 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
Alanine SCHEMBL18770349 0.93 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
Alanine SCHEMBL18770348 0.93 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2310526 0.89 SLC7A5 (0.83) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL8121390 0.84 EPHX1 (0.50) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 792 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS ENDEVICA BIO INC (US) 2026-04-09 US claimed
EP-4696699-A1 ? OPIOID RECEPTOR AGONIST AND USE THEREOF Chengdu Aoda Biotechnology Co., Ltd. (CN) 2026-02-18 EP claimed
EP-4696700-A1 LONG-ACTING K-OPIOID RECEPTOR AGONIST Chengdu Aoda Biotechnology Co., Ltd (CN) 2026-02-18 EP claimed
EP-4665374-A1 METHODS OF PREVENTING AND/OR TREATING SIDE EFFECTS ASSOCIATED WITH ANTI-CANCER AGENTS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS WITH ANTI-GDF-15 ANTIBODIES Endevica Bio, Inc. (US) 2025-12-24 EP claimed
WO-2025245279-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245294-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
EP-4605407-A2 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS Endevica Bio, Inc. (US) 2025-08-27 EP claimed
CN-120192379-A Marine cyclic peptide and synthesis method and application thereof 内蒙古大学 2025-06-24 CN claimed
WO-2025123059-A1 NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR TREATING SUBSTANCE USE DISORDERS ENDEVICA BIO, INC. (US) 2025-06-12 WO claimed
WO-2025123055-A1 NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-06-12 WO claimed
US-20140336216-A1 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-11-13 US claimed
WO-2014152917-A2 PHYSIOLOGICAL LIGANDS FOR GPR139 JANSSEN PHARMACEUTICA NV (BE) 2014-09-25 WO claimed
US-20080233137-A1 Compounds that Block the C5a Receptor and Their Use in Therapy ALLIGATOR BIOSCIENCE AB (SE) 2008-09-25 US claimed
CN-1997664-A Compounds that block the C5A receptor and their use in therapy ALLIGATOR BIOSCIENCE AB PUBL (SE) 2007-07-11 CN claimed
EP-1737886-A2 COMPOUNDS THAT BLOCK THE C5A RECEPTOR AND THEIR USE IN THERAPY Alligator Bioscience AB (publ) (SE) 2007-01-03 EP claimed
WO-2005100385-A2 COMPOUNDS THAT BLOCK THE C5A RECEPTOR AND THEIR USE IN THERAPY ALLIGATOR BIOSCIENCE AB (PUBL) (SE) 2005-10-27 WO claimed
EP-1586583-A2 Compounds that block C5a complement receptor and their use in therapy Alligator Bioscience AB (publ) (SE) 2005-10-19 EP claimed
WO-2003006048-A1 COMBINATION OF CHIPS (CHEMOTAXIS INHIBITING PROTEIN FROM STAPHYLOCOCCUS AUREUS)-BASED COMPOUNDS JARI PHARMACEUTICALS B.V. (NL) 2003-01-23 WO claimed
EP-1025127-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES Wapharm AB (SE) 2000-08-09 EP claimed
WO-1998037097-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES WAPHARM AB (SE) 1998-08-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS MC1R, MC4R, MC5R SLC7A5 161/4885PTGS1 2336/4885ALPI 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.